Paul D Allen Selected Research

Malignant Hyperthermia

10/2021	Ryanodine receptor leak triggers fiber Ca2+ redistribution to preserve force and elevate basal metabolism in skeletal muscle.
1/2021	T lymphocytes from malignant hyperthermia-susceptible mice display aberrations in intracellular calcium signaling and mitochondrial function.
1/2021	Molecular Modification of Transient Receptor Potential Canonical 6 Channels Modulates Calcium Dyshomeostasis in a Mouse Model Relevant to Malignant Hyperthermia.
1/2021	A novel RyR1-selective inhibitor prevents and rescues sudden death in mouse models of malignant hyperthermia and heat stroke.
11/2020	Bioenergetic defects in muscle fibers of RYR1 mutant knock-in mice associated with malignant hyperthermia.
1/2020	Transient Receptor Potential Cation Channels and Calcium Dyshomeostasis in a Mouse Model Relevant to Malignant Hyperthermia.
1/2020	Sex-specific alterations in whole body energetics and voluntary activity in heterozygous R163C malignant hyperthermia-susceptible mice.
3/2013	Nonspecific sarcolemmal cation channels are critical for the pathogenesis of malignant hyperthermia.
5/2012	Malignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptor.
3/2012	Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul D Allen Research Topics

Disease

22	Malignant Hyperthermia 10/2021 - 07/2003
6	Duchenne Muscular Dystrophy (Muscular Dystrophy, Becker) 01/2020 - 01/2002
4	Muscular Diseases (Myopathy) 10/2021 - 01/2002
4	Heart Failure 11/2007 - 06/2002
2	Heat Stroke (Heatstroke) 10/2021 - 01/2021
2	Neoplasms (Cancer) 03/2018 - 10/2007
2	X-Linked Genetic Diseases 07/2015 - 01/2013
2	Muscular Dystrophies (Muscular Dystrophy) 06/2014 - 01/2014
2	Inborn Genetic Diseases (Disease, Hereditary) 01/2014 - 06/2012
2	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 11/2007 - 06/2002
2	Alzheimer Disease (Alzheimer's Disease) 10/2006 - 12/2004
2	Inclusion Body Myositis 10/2006 - 12/2004
1	Rhinosinusitis 02/2021
1	Contracture 01/2021
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021
1	Fibrosis (Cirrhosis) 01/2021
1	Hyperthermia 01/2020
1	Mitochondrial Diseases (Mitochondrial Disease) 05/2019
1	Sepsis (Septicemia) 02/2016
1	Pyelonephritis 02/2016
1	Chronic Renal Insufficiency 02/2016
1	Ototoxicity 02/2016
1	Asthma (Bronchial Asthma) 01/2013
1	Inflammation (Inflammations) 06/2012
1	Prostatic Neoplasms (Prostate Cancer) 01/2012
1	Central Core Myopathy (Central Core Disease) 01/2011
1	Insulin Resistance 01/2011
1	Cardiac Arrhythmias (Arrythmia) 05/2009
1	Thrombocytopenia (Thrombopenia) 08/2008
1	Necrosis 08/2008
1	Spasm (Spasms) 04/2008
1	Heart Diseases (Heart Disease) 11/2007
1	Cardiomyopathies (Cardiomyopathy) 11/2007
1	Aortic Valve Stenosis (Aortic Stenosis) 11/2007
1	Myeloid Leukemia (Leukemia, Myelocytic) 10/2007
1	Leukemia 10/2007
1	Acidosis 12/2006
1	Rigor Mortis 12/2006
1	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2006
1	Hypertrophy 08/2005
1	Chagas Cardiomyopathy 08/2005
1	Infections 03/2005
1	Glioma (Gliomas) 12/2002

Drug/Important Bio-Agent (IBA)

19	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 10/2021 - 07/2003
7	Proteins (Proteins, Gene)FDA Link 01/2020 - 12/2002
6	CalciumIBA 01/2021 - 05/2007
5	Halothane (Fluothane)FDA Link 01/2021 - 12/2006
5	DystrophinIBA 07/2015 - 01/2002
4	Caffeine (No Doz)FDA LinkGeneric 01/2021 - 03/2005
4	Anesthetics (Anesthetic Agents)IBA 01/2021 - 03/2005
4	CationsIBA 01/2021 - 03/2013
2	SodiumIBA 01/2021 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2013 - 01/2012
2	CytokinesIBA 01/2013 - 08/2005
2	Dantrolene (Dantrium)FDA LinkGeneric 04/2008 - 12/2006
2	Complementary DNA (cDNA)IBA 08/2005 - 06/2002
1	XylitolIBA 02/2021
1	Isoflurane FDA LinkGeneric 01/2021
1	AcidsIBA 01/2021
1	Oxolinic AcidIBA 01/2021
1	TRPC6 Cation ChannelIBA 01/2021
1	Transient Receptor Potential ChannelsIBA 01/2020
1	ParaffinIBA 03/2018
1	Formaldehyde (Formol)FDA Link 03/2018
1	Gentamicins (Gentamicin)FDA LinkGeneric 02/2016
1	Sarcoglycans (beta Sarcoglycan)IBA 06/2014
1	Sodium-Calcium ExchangerIBA 06/2014
1	Calcium Channels (Calcium Channel)IBA 01/2012
1	Messenger RNA (mRNA)IBA 01/2012
1	CalcineurinIBA 01/2011
1	triadinIBA 05/2009
1	Ethidium (Ethidium Bromide)IBA 08/2008
1	Annexin A5IBA 08/2008
1	Propidium (Propidium Iodide)IBA 08/2008
1	Membrane LipidsIBA 08/2008
1	Pharmaceutical PreparationsIBA 04/2008
1	BuffersIBA 12/2007
1	MicroRNAs (MicroRNA)IBA 11/2007
1	Etoposide (VP 16)FDA LinkGeneric 10/2007
1	Complement System Proteins (Complement)IBA 10/2007
1	Aurora Kinase BIBA 10/2007
1	Topoisomerase InhibitorsIBA 10/2007
1	Neuromuscular Agents (Skeletal Muscle Relaxants)IBA 05/2007
1	Inhalation AnestheticsIBA 05/2007
1	RyanodineIBA 12/2006
1	Amyloid beta-PeptidesIBA 10/2006
1	Peptides (Polypeptides)IBA 10/2006
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 08/2005
1	InterferonsIBA 08/2005
1	ChemokinesIBA 08/2005
1	Neuromuscular Depolarizing AgentsIBA 03/2005
1	Cyclic ADP-Ribose (cADPR)IBA 01/2005
1	L-Type Calcium Channels (Dihydropyridine Receptor)IBA 10/2004
1	Genetic Markers (Genetic Marker)IBA 07/2002

Therapy/Procedure

4	Therapeutics 02/2021 - 01/2002
1	Drug Therapy (Chemotherapy) 01/2021
1	Radiotherapy 01/2021
1	Anesthesia 01/2021
1	Transplantation 01/2002